We have retrospectively studied 118 eyes of 91 diabetic patients which underwent cataract surgery and followed up at least 3 months and the postoperative corrected visual acuity compared according to the degree of retinopathy, duration of diabetics and age of the patients The results were as follows: 1. Age distribution of the diabetic patients were 17-85 years old and 6th decade was most frequent group and the percentage of male patients were 64.8% and 82.4% of total patients were over 50 years of age. 2. The postoperative corrected visual acuity above 20/40 according to patient age was 100% in the 3rd decade and 1st decade, 87.5% in the 4th decade, 73.5% in the 5th decade, 80.9% in the 6th decade and 42.8% in the 2nd decade. The postoperative visual acuity was generally better in younger patients. 3. The postoperative corrected visual acutiy above 20/40 according to degree of diabetics was 94.2% in Non Diabetic Retinopathy, 78.5% in Background Diabetic Retinopathy, 11.1% in Proliferative Diabetic Retinophthy. The postoperative corrected visual acuity was worse in severe retinopthy group. 4. The postoperative corrected visual acuity above 20/40 according to duration of diabetics was 94.2% in under 5 years, 83.9% in 10 < -15 years, 56.1% in above 15 years and the result was better in short diabetic duraction group.
Age Distribution ; Cataract* ; Diabetic Retinopathy ; Humans ; Male ; Retrospective Studies ; Visual Acuity

We have retrospectively studied 118 eyes of 91 diabetic patients which underwent cataract surgery and followed up at least 3 months and the postoperative corrected visual acuity compared according to the degree of retinopathy, duration of diabetics and age of the patients The results were as follows: 1. Age distribution of the diabetic patients were 17-85 years old and 6th decade was most frequent group and the percentage of male patients were 64.8% and 82.4% of total patients were over 50 years of age. 2. The postoperative corrected visual acuity above 20/40 according to patient age was 100% in the 3rd decade and 1st decade, 87.5% in the 4th decade, 73.5% in the 5th decade, 80.9% in the 6th decade and 42.8% in the 2nd decade. The postoperative visual acuity was generally better in younger patients. 3. The postoperative corrected visual acutiy above 20/40 according to degree of diabetics was 94.2% in Non Diabetic Retinopathy, 78.5% in Background Diabetic Retinopathy, 11.1% in Proliferative Diabetic Retinophthy. The postoperative corrected visual acuity was worse in severe retinopthy group. 4. The postoperative corrected visual acuity above 20/40 according to duration of diabetics was 94.2% in under 5 years, 83.9% in 10 < -15 years, 56.1% in above 15 years and the result was better in short diabetic duraction group.
Age Distribution ; Cataract* ; Diabetic Retinopathy ; Humans ; Male ; Retrospective Studies ; Visual Acuity

PURPOSE: To gain insight on transcriptional repression of Topo II a in HL-60 cells arrested to G2/M and M phase, the levels of Topo IIa mRNA and the binding activity of ATF have been investigated with Northern blot hybridization and DNA mobility shift assay, respectively. MATERIALS AND METHODS: HL-60 cells were grown in RPMI 1640 medium supplemented with 10% heat-mactivated fetal bovine serum and antibiotics in a humidified 5% CO2 at 37C degree. Total RNA was prepared by a modification of the method of Karlinsey et al. Northern blot hybridization was performed by the method of Virca et al. A Xho I-Mlu I fragment of phTOP2 was used as probe for Northern blot analysis of Topo II a mRNA. DNA mobility shift assay was performed by the method of Lim et al. End labeled DNA oligomer (upper strand, 5-TCTCCGCTATGACGCCGAGTGGTG-3) for ATF binding activity was mixed with nuclear extracts in a 20 pl reaction volume containing 60 mM KC1, 12 mM HEPES, pH 7.9, 5 mM MgCl2, 0.2 mM EDTA, 0.2 mM DTT, 12% glycerol, and 2 ug of poly [dI-dC]. RESULTS: HL-60 cells were arrested at G2/M phase and M phase after taxol or nocodazole treatment. The levels of Topo II a mRNA were reduced at 24 hours after exposure with nocodazole or taxol but the unknotting activities were not changed. DNA mobility shift assay using oligonucleotide containing the ATF binding site showed that ATF binding activity was reduced after pretreatment of nododazole or taxol. CONCLUSIONS: These results suggest that the reduction of ATF binding activity may be important to transcriptional repression of Topo II a gene by nocodazole and taxol in HL- 60 cells.
Anti-Bacterial Agents ; Binding Sites ; Blotting, Northern ; Cell Division* ; DNA Topoisomerases, Type I* ; DNA Topoisomerases, Type II* ; DNA* ; Edetic Acid ; Electrophoretic Mobility Shift Assay ; Genes, vif ; Glycerol ; HEPES ; HL-60 Cells ; Humans ; Hydrogen-Ion Concentration ; Magnesium Chloride ; Nocodazole ; Paclitaxel ; Repression, Psychology ; RNA ; RNA, Messenger

In order to assess the prevalence of ocular disorders of the aged patients, retrospective survey was carried out in 5,659 patients over the age of 60, who visited outpatient clinics of three hospitals (St. Mary's Hospital, Cheonnam University Hospital and Inha University Hospital) between 1989 and 1990. An analysis of data was resulted in as follow: 1. Proportion of the aged patients to total out-patients was 15%. 2. The age distributions of patients were sixties (59%), seventies (34%), over eighty (7%). 3. In the patient 60 years old and older, 36.9% of the cases had best corrected visual acuities of 0.7 or better. 4. The most prevalent ocular disorder was senile cataract (44.0%), and others included conjunctival and scleral diseases (14.9%), retinal diseases (14.4%), refractive error (9.1%), glaucoma (4.4%), and corneal diseases (3.2%). 5. The proportion of causes of blindness indicates; senile cataract (58.8%), retinal diseases (15.4%), glaucoma (6.8%), and corneal diseases (5.0%), etc. 6. The systemic disorders associated with ocular diseases were hypertension 7.0%, diabetes 5.0%, respiratory diseases 4.2%, and heart diseases 2.0%. 7. Visual acuities better than 0.4 were obtained in 87.4% of postoperative cataract surgeries in aged patients.
Age Distribution ; Ambulatory Care Facilities ; Blindness ; Cataract ; Corneal Diseases ; Glaucoma ; Heart Diseases ; Humans ; Hypertension ; Middle Aged ; Outpatients ; Prevalence* ; Refractive Errors ; Retinal Diseases ; Retrospective Studies ; Scleral Diseases ; Visual Acuity

PURPOSE: Angiostatin, a 38 kDa internal fragment of plasminogen, is a potent inhibitor of angiogenesis. It blocks neovascularization and growth of primary and metastatic tumors in mice. To produce recombinant angiostatin protem comprising kringle 1-4 of plasminogen, we cloned the angiostatin cDNA from human liver tissue mRNA and expressed it in E. coli. MATERIALS AND METHODS: We cloned angiostatin cDNA from human liver tissue mRNA using reverse transcriptase polymerase chain reaction (RT-PCR) method. Cloned cDNA was ligated to pET22b (+) expression vector, transformed into E. coli stram BL21 (DE3) and expressed by IPTG induction. Recombinant human angiostatin protein was purified from the inclusion bodies of lysated bacterial pellet with 8 M urea solubilization, refolding, single step Lysine-Sepharose 4B affinity chromatography and 0.2 M E-aminocarproic acid elution. The anti-angiogenic activity of purified recombinant angiostatin was assayed with endothelial cell proliferation assay and chorioallantoic membrane assay (CAM). RESULTS: The identification of cloned angiostatin cDNA was confirmed by Southern hybridization and Pst I restriction enzyme digestion pattern. Angiostatin cDNA was expressed in E. coli, refolded in vitro and purified by Lysine Sepharose 4B affinity chromatography. The molecular weight of purified recombinant angiostatin was about 55 kDa on the SDS-PAGE. It inhibited the proliferation of bovine capillary endothelial (BCE) cells in vitro with a half-maximal inhibition concentration (ED50) of approximately 500 ng/mL. It also suppressed neovasculrization on the CAM assay. CONCLUSION: These results demonstrated that recombinant human angiostatin has similar function and biological activity compared with human angiostatin which is purified from porcine elastase digested human plasminogen fragment.
Angiostatins* ; Animals ; Capillaries ; Chorioallantoic Membrane ; Chromatography, Affinity ; Clone Cells* ; Cloning, Organism* ; Digestion ; DNA, Complementary* ; Electrophoresis, Polyacrylamide Gel ; Endothelial Cells ; Humans* ; Inclusion Bodies ; Isopropyl Thiogalactoside ; Kringles ; Liver* ; Lysine ; Mice ; Molecular Weight ; Pancreatic Elastase ; Plasminogen ; Reverse Transcriptase Polymerase Chain Reaction ; RNA, Messenger* ; Sepharose ; Urea

A 26-year-old man with intermittent lower, abdominal, cramping pain, nausea, vomiting, and diarrhea was found to have intussusception by computed tomography. Whole emergency laparotomy was performed, intus-susception reduced spontaneously. Postoperately, familial adenomatous polyposis (FAP) was diagnosed by colonoscopy and barium enema. Innumerous polyps were found in the entire colon and one of these was presumed to have caused sigmoid invagination. If is believed that FAP is quite a rare cause of colonic intus-susception. This case of a 26-year-old man with an intussusception of the colon due to FAP is herein reported. It is important that surgeons and internists are aware of this rare cause of intussusception due to FAP because of the therapeutic implications.
Adenomatous Polyposis Coli* ; Adult ; Barium ; Colon* ; Colon, Sigmoid ; Colonoscopy ; Diarrhea ; Emergencies ; Enema ; Humans ; Intussusception* ; Laparotomy ; Muscle Cramp ; Nausea ; Polyps ; Vomiting

Pulmonary blastoma are a family of tumors in which the glands or mesenchyme composing the neoplasm are primitive or embryonal in appearance. We report a pulmonary blastoma occurring in a 31 years old man. An abnormal shadow was detected in the right lower lung field in a routine chest X-ray film. The preoperative imaging films showed about a 5cm sized well circumscribed solid tumor of the right lung. A preoperative clinical diagnosis of primary lung cancer was considerd. The operative field showed that the hard, round mass, 6 x 5 x 4cm in diameter was localized in middle lobe of the right lung, and partially adhered to the upper lobe, pericardium and diaphragm. Right middle lobe lobectomy, right upper lobe wedge resection, partial pericardiectomy and diaphragm resection with plication was performed with radical lymph node dissection. Histopathologic diagnosis was pulmonary blastoma (Biphasic blastoma). It is considered that the prognosis of biphasic blastoma is worse than WDFA(well differentiated fetal adenocarcinoma). There are no other available treatments except for surgical resection. It is suggested that it is necessary to collect as many cases as possible, to make definite classifications and to examine the clinical course and prognosis of pulmonary blastoma.
Adult ; Classification ; Diagnosis ; Diaphragm ; Humans ; Lung ; Lung Neoplasms ; Lymph Node Excision ; Mesoderm ; Pericardiectomy ; Pericardium ; Prognosis ; Pulmonary Blastoma* ; Thorax ; X-Ray Film

We aimed to determine the characteristic adverse events (AEs) of iodinated contrast media (IOCM) and to compare the safety profiles of different IOCM. This study used the database of AEs reports submitted by healthcare professionals from 15 Regional Pharmacovigilance Centers between June 24, 2009 and December 31, 2010 in Korea. All reports of IOCM, including iopromide, iohexol, iopamidol, iomeprol, ioversol, iobitridol and iodixanol, were analyzed. Safety profiles were compared between different IOCM at the system organ level using the proportional reporting ratio (PRR) and 95% confidence interval (95% CI). Among a total of 48,261 reports, 6,524 (13.5%) reports were related to the use of IOCM. Iopromide (45.5%), iohexol (16.9%), iopamidol (14.3%) and iomeprol (10.3%) were identified as frequently reported media. 'Platelet, bleeding & clotting disorders' (PRR, 29.6; 95%CI, 1.9-472.6) and 'urinary system disorders' (PRR, 22.3; 95% CI, 17.1-29.1) were more frequently reported for iodixanol than the other IOCM. In conclusion, the frequency of AEs by organ class was significantly different between individual media. These differences among different IOCM should be considered when selecting a medium among various IOCM and when monitoring patients during and after its use to ensure optimum usage and patient safety.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Blood Platelet Disorders/chemically induced ; Child ; Child, Preschool ; Contrast Media/*adverse effects/diagnostic use ; Databases, Factual ; Female ; Humans ; Infant ; Infant, Newborn ; Iodine Radioisotopes/chemistry ; Male ; Middle Aged ; Neoplasms/radionuclide imaging ; Radiopharmaceuticals/*adverse effects/diagnostic use ; Urologic Diseases/chemically induced ; Young Adult

BACKGROUND: New stent implantation during intracoronary brachytherapy is discouraged due to the high risk of late thrombosis. However, new stent implantation is inevitable in some cases due to the inadequate ballooning or major dissections. Long-term follow-up results of newly implanted stents during brachytherapy are not well-known. We performed this study to evaluate the long-term clinical outcomes of newly implanted stents during intracoronary brachytherapy. METHODS: In the Seoul national university Post-Angioplasty RhEnium irradiation (SPARE) trial, patients were treated with conventional catheter-based technique and then randomized to either beta- radiation (RG) or control group (CG). Radiation was performed with 188 -rhenium-filled conventional balloon catheter system. From 1999 to 2001, new stent implantation was performed in 58 and 56 patients in RG and CG, respectively. Clinical and angiographic follow up data were analyzed. RESULTS: In RG, short-term angiographic restenosis rate was lower than CG (28.6% vs 53%, p=0.03). In RG, late thrombosis was found in 3 patients. However, there was no late thrombosis in CG. Two year major cardiac event rates were not different between the 2 groups (RG: 25.9% vs CG: 28.3%). Independent predictors for major cardiac event in RG were major dissections (>or=type C) after stent implantation (beta=70, p=0.01) and longer administration of dual antiplatelets (aspirin+clopidogrel/ ticlopidine, >6 months, beta=0.07, p=0.04). CONCLUSION: Stenting during intracoronary brachytherapy seems to be ineffective in reducing long-term event rates. When new stent implantation is inevitable during brachytherapy, extreme attention is required not to make a dissection and long-term dual antiplatelet treatment should be followed after stent implantation.
Angioplasty ; Brachytherapy ; Catheters ; Follow-Up Studies ; Humans ; Rhenium ; Seoul ; Stents* ; Thrombosis ; Ticlopidine

OBJECTIVES: The poor survival rates among patients receiving surgery alone for stages II and III non-small cell lung cancer prompted several trials of adjuvant therapy after resection. We performed a prospective phase II study in patients with stage II-IIIA non-small cell lung cancer after resection to evaluate the feasibility, activity and toxicity of the postoperative sequential MVP chemotherapy and radiotherapy. METHODS: Between February 1991 and May 1995, 60 patients with resected stage II, IIIA non-small cell lung cancer received 2 cycles of MVP combination chemotherapy (Mitomycin-C 6 mg/m2, Vinblastine 6 mg/m2, Cisplatin 60 mg/m2) within 3 weeks after surgery, followed by thoracic irradiation (5,040 cGy after complete resection and 900 cGy booster to microscopically positive resection margin at 1.8 Gy per fraction) within 3-4 weeks after chemotherapy. RESULTS: Forty nine men and 11 women with a median age of 60.5 years (range 33-81 years) were included. During the median follow-up period of 828 days (61-2,015 days), 25 patients had developed recurrence. Among the 25 failures, 3 were local relapse only and 20 were distant metastasis only and 2 had both local and distant sites of recurrence. Three-year overall survival and event-free survival were 43% and 37%, respectively. Neutropenia of grade I-II was observed only in 13 patients. Eleven patient showed grade I-II radiation pneumonitis and 32 had grade I-II radiation esophagitis. CONCLUSION: Postoperative sequential MVP chemotherapy and radiotherapy in resected stage II-IIIA non-small cell lung cancer is well-tolerated and shows interesting activity.
Carcinoma, Non-Small-Cell Lung* ; Cisplatin* ; Disease-Free Survival ; Drug Therapy* ; Drug Therapy, Combination ; Esophagitis ; Female ; Follow-Up Studies ; Humans ; Male ; Mitomycin* ; Neoplasm Metastasis ; Neutropenia ; Prospective Studies ; Radiation Pneumonitis ; Radiotherapy* ; Recurrence ; Survival Rate ; Vinblastine*